Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
May 30, 2024
May 30, 2024
NEW BRUNSWICK, New Jersey, May 30 -- Johnson & Johnson issued the following news release on May 28, 2024:
* * *
The Company/1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary/2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD)
NM26 has the potential to offer distinctive benefits versus existing treatments and . . .
* * *
The Company/1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary/2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD)
NM26 has the potential to offer distinctive benefits versus existing treatments and . . .